Keyword: Apellis Pharmaceuticals
The result suggests Apellis can challenge Alexion’s dominance in paroxysmal nocturnal hemoglobinuria.
The resumption follows modifications to the production process to cut the risk of the noninfectious inflammation that triggered the halt.
After halting phase 3 trials for its APL-2 drug in geographic atrophy on safety concerns, Apellis says it will restart the program next year.
Novartis Oncology head Bruno Strigini retires, Amneal poaches Allergan's Robert Stewart, plus more hirings, firings and retirings across the industry.
Flushed with recent clinical trial wins, Apellis has moved quickly ahead with an initial public offering.
Apellis reported positive midstage data for its lead candidate in age-related macular degeneration shortly after a $60 million series E raise.